Biogen walks away from an Alzheimer's drug

Biogen is giving up its ownership of Aduhelm, the Alzheimer's disease treatment whose 2021 approval led to scrutiny and outrage.

January 31, 2024 Check out STAT+

Sponsored By

Jessica Rinaldi/The Boston Globe STAT+ | Years after a polarizing approval, Biogen walks away from Aduhelm Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. By Damian Garde STAT+ | Experts critique flawed system for monitoring drugs' side effects in wake of asthma drug report The FDA's Adverse Event Reporting System needs modernization, experts say, with links to EHRs and better warning label strategies. By Theresa Gaffney STAT+ | As supply crunch starts to ease, Novo Nordisk to offer more doses of obesity drug Wegovy to U.S. patients The company had limited starter doses in the U.S. last year in the face of overwhelming demand and limited supply. By Andrew Joseph Adobe STAT+ | Judge skeptical of arguments against Medicare drug price negotiation A judge grilled industry lawyers today over their contention that Medicare's drug price negotiation program is unconstitutional. By John Wilkerson Cigna to sell Medicare Advantage plans to Blue Cross Blue Shield insurer for $3.3 billion Cigna is officially exiting the Medicare business, agreeing to sell all of its MA plans to Health Care Service Corp. for $3.3 billion. By Bob Herman Some dementia patients might have reversible symptoms caused by cirrhosis, study says Hepatic encephalopathy in cirrhosis patients mirrors dementia but can be treated. A new analysis suggests liver disease is often missed. By Isabella Cueto Adobe We're naming cancers all wrong, oncology leader says Two types of breast cancer, one triple negative, the other with HER2 proteins, is one example of how the same name has different treatments. By Angus Chen STAT+ | WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies The effort began in June 2022, after the WTO reached a five-year arrangement to waive patent rights for Covid-19 vaccines. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser